QCZ484 placebo

Phase 2

Novartis

QCZ484 placebo is one of 3 therapeutic programs targeting Hypercholesterolaemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HypercholesterolaemiaRecruiting

HypercholesterolaemiaPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Hypercholesterolaemia

#DrugCompanyPhaseTrials

Leqvio

Novartis

Phase 2

1 2

QCZ484

Novartis

Phase 2

1 3

QCZ484 placebo

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Hypercholesterolaemia

NCT07610278

Clinical

Trials by Indication[1]

Hypercholesterolaemia1 trial

A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia

Recruiting· Novartis logo

Novartis·Phase 2·NCT07610278·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for QCZ484 placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for QCZ484 placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Novartis

QCZ484 placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Hypercholesterolaemia1 trial

References

Drug Info

Quick Facts

Related News